Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer

Acta Oncologica

Volumn 50, Issue 3, 2011, Pages 415-419

  Risum, Signe ^a   Loft, Annika ^b   Høgdall, Claus ^c   Berthelsen, Anne K ^b   Høgdall, Estrid ^b   Lundvall, Lene ^c   Nedergaard, Lotte ^b   Engelholm, Svend A ^a  

^a FINSEN LABORATORY   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CONTRAST MEDIUM; DOCETAXEL; FLUORODEOXYGLUCOSE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DRUG UPTAKE; FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; MINIMAL RESIDUAL DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVARY CANCER; PELVIS TUMOR; PHYSICAL PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RISK OF MALIGNACY INDEX; STANDARDIZED UPTAKE VALUE; ULTRASOUND;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; OVARIECTOMY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 79952657079     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.500296     Document Type: Article

References (25)

1. Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: A clinical perspective. Nucl Med Commun 2004;25:651-6. (Pubitemid 38901681)
2. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007;110:1738-44. (Pubitemid 47557298)
3. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi eA, Lehmann W, et al. Standardized uptake value of 2-(18)F. fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002;20:1398-404. (Pubitemid 34177448)
4. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-60. (Pubitemid 41103680)
5. Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006;82:391-4.
6. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003;7:953-9.
7. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy- 2-fluoro18F.-D-glucose. Cancer 1998;82:2227-34. (Pubitemid 28240830)
8. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93:448-52. (Pubitemid 29107011)
9. Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-18F.deoxyglucose (2-18F.FDG). Gynecol Oncol 1993;51:197-204.
10. Cox D. Regression models and life tables. J R Stat Soc B 1972;34:187-202.
11. Kaplan E, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
12. Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med 2004;45:930-2. (Pubitemid 47611678)
13. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
14. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9.
15. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: Rationale use of a triage system. Gynecol Oncol 2007;105: 84-9. (Pubitemid 46441445)
16. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:227-31. (Pubitemid 30317140)
17. de Jong D, Eijkemans MJ, Lie FS, Gerestein CG, Kooi GS, Baalbergen A, et al. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma. Oncology 2007;72:293-301. (Pubitemid 351238140)
18. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography-a prospective study. Gynecol Oncol 2008;108:265-70. (Pubitemid 351181445)
19. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007;25:384-9. (Pubitemid 350002986)
20. Kumar R, Alavi A. PET imaging in gynecologic malignancies. Radiol Clin North Am 2004;42:1155-67. (Pubitemid 39361466)
21. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol Oncol 2007;105:145-9. (Pubitemid 46454333)
22. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53. (Pubitemid 46291806)
23. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 2009;50:64-73.
24. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90:519-28.
25. Risum S, Hogdall C, Markova E, Berthelsen AK, Loft A, Jensen F, et al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer 2009;19:600-4.